Phase 4 Heart Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults aged 19 years or older
- People experiencing typical chest pain, or who have test results showing reduced blood flow to the heart, where a procedure to open blocked arteries (called PCI) is considered appropriate
- People who have new blockages in their heart arteries that are suitable for treatment with a drug-coated stent
- People whose stent was placed using a specialised imaging technique (either IVUS or OCT) during the procedure, and where the imaging confirmed the stent was well-positioned and met specific measurement standards (confirm exact technical details with trial site)
- People who have read and signed a written consent form agreeing to take part and attend follow-up appointments, as approved by the relevant ethics committee
Who may not be able to join:
- People whose blocked artery is located in a bypass graft
- People whose artery blockage is in a location where the imaging equipment would be difficult to use — for example, where the artery has a very sharp bend, excessive twisting, or heavy calcium deposits near or within the blockage
- People who have a previously treated artery where the stent has re-narrowed (in-stent restenosis)
- People who have a known allergy or sensitivity to the materials in the stent device, including cobalt, chromium, nickel, platinum, tungsten, or certain polymers, that cannot be managed with prior medication
- People with a persistently low platelet count (a type of blood cell important for clotting) below a certain level
- People who have ever had a bleeding stroke or bleeding in the brain, or who have had a mini-stroke or ischemic stroke within the past 6 months
- People with a known allergy or intolerance to aspirin, clopidogrel, ticagrelor, or heparin (blood-thinning medications used in this type of procedure)
- People who need to take long-term blood-thinning tablets (oral anticoagulants) or a medication called cilostazol
- People who have surgery planned within 12 months after the procedure that would require general anaesthesia or stopping blood-thinning medications
- People who have been diagnosed with cancer (other than certain minor skin cancers) in the past 3 years, or who are currently being treated for cancer
- People who have a significant abnormal finding on examination, blood tests, or heart tracing that the study doctor believes would make it unsafe to participate
- People with a history of advanced liver disease (Child-Pugh B or C) or a blockage in the bile ducts
- People whose life expectancy is less than 1 year for any reason
- People who were in cardiogenic shock (a serious condition where the heart cannot pump enough blood) at the time of their hospital admission
- People who are pregnant or breastfeeding
- People who are actively bleeding or are considered to be at very high risk of serious bleeding (for example, due to active stomach ulcers, certain bowel conditions, or cancers with a high bleeding risk)
- People who are unwilling or unable to follow the procedures required by the study
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 82 2-2045-3798
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
1) clinically relevant bleeding [Bleeding Academic Research Consortium (BARC) 2, 3, or 5]; 2) net clinical outcome defined as a composite of all-cause death, MI, ischemia-driven target vessel revascularization (TVR), definite/probable stent thrombosis (ST), and clinically relevant bleeding [BARC 2, 3, or 5]; 3) ischemic composite adverse event of all-cause death, MI, ischemia-driven target vessel revascularization (TVR), definite/probable stent thrombosis (ST)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.